💊 Get Daily Updates on Generic Entry, Litigation, Biosimilars, and More…
Profile for Compugen Ltd. (CGEN)
« Back to company indexCGEN Chatter Timeline
Stock Ticker for CGEN
Most Active Tweeters for CGEN
| User | Tweets |
|---|---|
| @CondottiereFIRE | 1 |
| @hadidy_sara | 1 |
| @MarcJacksonLA | 1 |
| @Steven38199694 | 1 |
| @wonenownlee | 1 |
Recent Tweets for CGEN
 |
@wonenownlee @PozziTony @NatHarooni What's happening with $CGEN, merger? Thoughts? April 16th 2021, 8:04pm |
 |
@MarcJacksonLA $CGEN How Computational Biology Birthed A Biopharma https://t.co/D9t4UHR4nt April 15th 2021, 4:04pm |
 |
@CondottiereFIRE Bought $CGEN shares for $8.63 April 14th 2021, 7:04pm |
 |
@Somerled1113 $CGEN is getting close. We could see a breakout real soon. #StockMarket #StocksToBuy #trading #wealth #stocks… https://t.co/lVyTzidV5e April 14th 2021, 10:04am |
 |
@TradeWithAlerts Large Print $CGEN Size: 150466 Price: 8.72 Time: 1600 Amount: $1,312,063.52 April 13th 2021, 8:04pm |
 |
@mnvasque RT @JacobPlieth: Did $CGEN just issue the first PR for #ASCO21? Tells us abstracts titles come out 28 April. We already knew that abstract… April 7th 2021, 11:04pm |
 |
@JacobPlieth Did $CGEN just issue the first PR for #ASCO21? Tells us abstracts titles come out 28 April. We already knew that ab… https://t.co/61HrnDL7rw April 7th 2021, 8:04am |
 |
@Steven38199694 $CGEN On Compugen's website today. $CGEN to present updated data on COM701 Phase 1 trial at ASCO 2021. Embargo will… https://t.co/s2XxIyNZ4x April 6th 2021, 6:04pm |
 |
@hadidy_sara CGEN: Signals on the 3-minute chart for $CGEN. Trading this is easy with the right algo to help. Get access to Ultr… https://t.co/Lc9qNUJLLP April 6th 2021, 4:04pm |
 |
@stockhoot $CGEN SVB Leerink Maintains to Outperform : PT $16.00 https://t.co/Xg5xJnqaF1 April 6th 2021, 11:04am |
|
@Steven38199694 $CGEN I just noticed that Compugen's triple combination trial (COM701 anti-PVRIG, $BMY's anti-TIGIT BMS986207 and… https://t.co/6NUS7jvvkq April 5th 2021, 6:04pm |
 |
@Gambiste1 RT @JanEhses: @JPZaragoza1 That's $CGEN not $CGEM April 1st 2021, 10:04am |
 |
@JanEhses @JPZaragoza1 That's $CGEN not $CGEM April 1st 2021, 10:04am |
 |
@sinjun74 RT @CompugenLtd: Today is #NationalDoctorsDay! We’d like to thank all the medical doctors we have on staff for their contributions to $CGEN… March 30th 2021, 3:03pm |
 |
@YuZhu4 RT @JanEhses: 3. $CGEN: COM701 (anti-PVRIG), combination with Opdivo® dose escalation study and monotherapy expansion cohorts at ASCO. 4.… March 30th 2021, 1:03pm |
|
@JanEhses 3. $CGEN: COM701 (anti-PVRIG), combination with Opdivo® dose escalation study and monotherapy expansion cohorts at… https://t.co/p3hbAaYUi6 March 30th 2021, 6:03am |
 |
@jsaintj92 During this I’ve reshuffled a few open positions and caught $cgen under $8 which feels like a fucking steal. Nothin… https://t.co/GL5IX5iIb6 March 26th 2021, 8:03pm |
 |
@SickEconomics Here is one such name that may come to suffer from "Arkenomics." $CGEN If so, we would see value there. They are… https://t.co/mgY6h4jgbl March 26th 2021, 7:03pm |
 |
@Dreesen18516498 @INArteCarloDoss How much overlap you reckon there will be with the $Arkk universe. If he comes up with $CGEN I mig… https://t.co/9ZwnjVlXdl March 25th 2021, 7:03am |
|
@TradeWithAlerts Large Print $CGEN Size: 124414 Price: 8.2 Time: 1600 Amount: $1,020,194.80 March 24th 2021, 8:03pm |
 |
@ChartMill $CGEN was analyzed by 7 analysts. The buy consensus is at 100%. So analysts seem to be very confident about $CGEN.… https://t.co/fDcD25PXM2 March 20th 2021, 6:03pm |
 |
@Janfr31 RT @MarcJacksonLA: $CGEN Oppenheimer Assigns A Buy Rating On Compugen, $19 PT https://t.co/YqkahdIRpH March 19th 2021, 11:03am |
 |
@PozziTony @LuoshengPeng @LanternPharma You may want to look at Compugen $CGEN “ From Code to Cure” March 19th 2021, 2:03am |
|
@MarcJacksonLA $CGEN Oppenheimer Assigns A Buy Rating On Compugen, $19 PT https://t.co/YqkahdIRpH March 18th 2021, 4:03pm |
 |
@areismu3 @FrazierVercetti Check out $CGEN March 15th 2021, 12:03am |
|
@Steven38199694 $CGEN Peer-reviewed article "Therapeutic Targeting of Checkpoint Inhibitors within the DNAM-1 Axis", co-written by… https://t.co/k3n3qU11eB March 11th 2021, 10:03pm |
 |
@AlertTrade REVERSALtoUP: $CGEN Compugen Ltd https://t.co/uuh5kgM2N0 ? ? TradeIdeas via ? https://t.co/ZgCyz4rX3x March 11th 2021, 5:03pm |
|
@TradeWithAlerts Large Print $CGEN Size: 199700 Price: 8.61 Time: 1436 Amount: $1,719,417.00 March 10th 2021, 7:03pm |
|
@ChartMill $CGEN was analyzed by 7 analysts. The buy consensus is at 100%. So analysts seem to be very confident about $CGEN.… https://t.co/zSIdBfqxTx March 10th 2021, 3:03pm |
 |
@1stOncology #Compugen to Present at the #Oppenheimer31stAnnualHealthcareConference $CGEN https://t.co/bHX5qYKkSj March 10th 2021, 8:03am |
 |
@hadj_zied @umarashraf28 I took $AQB and $Cgen March 9th 2021, 8:03pm |
|
@MarcJacksonLA $CGEN Compugen Publishes Review Of DNAM-1 axis In Cancer Immunotherapy https://t.co/NdGfqFoSt4 March 9th 2021, 5:03pm |
 |
@SmallCapsDaily $CGEN Compugen Publishes Review on Biology and Potential Therapeutic Relevance of DNAM-1 axis in Cancer Immunothera… https://t.co/TbE7oYj6XZ March 9th 2021, 3:03pm |
 |
@Briefingcom $CGEN: Compugen announced the publication of a review article titled "Therapeutic Targeting of Checkpoint Receptors… https://t.co/7AoUf98b8y March 9th 2021, 2:03pm |
 |
@OpenOutcrier $CGEN (+4.4% pre) Compugen Publishes Review on Biology and Potential Therapeutic Relevance of DNAM-1 axis in Cancer… https://t.co/qhdLo0EZ9f March 9th 2021, 12:03pm |
 |
@StockNewsBot2 $CGEN Compugen Publishes Review on Biology and Potential Therapeutic Relevance of DNAM-1 axis in Cancer Immunotherapy March 9th 2021, 12:03pm |
 |
@ZoZoStockwatch RT @TheTradeXchange: $CGEN: Compugen Publishes Review on Biology and Potential Therapeutic Relevance of DNAM-1 axis in Cancer Immunotherapy March 9th 2021, 12:03pm |
 |
@TheTradeXchange $CGEN: Compugen Publishes Review on Biology and Potential Therapeutic Relevance of DNAM-1 axis in Cancer Immunotherapy March 9th 2021, 12:03pm |
 |
@stock_titan $CGEN Compugen Publishes Review on Biology and Potential Therapeutic Relevance of DNAM-1 axis in Cancer Immunothera… https://t.co/9v9Q9Ko5DL March 9th 2021, 12:03pm |
|
@MarcJacksonLA $CGEN Compugen to Present at the Oppenheimer 31st Annual Healthcare Conference https://t.co/HBikBShsMl March 8th 2021, 5:03pm |
|
@SmallCapsDaily $CGEN Compugen to Present at the Oppenheimer 31st Annual Healthcare Conference PR Newswire https://t.co/FvUtaKQCpZ… https://t.co/oIvvrP3Grd March 8th 2021, 3:03pm |
|
@StockNewsBot2 $CGEN Compugen to Present at the Oppenheimer 31st Annual Healthcare Conference March 8th 2021, 12:03pm |
 |
@PRNewswireIL #Compugen to #Present at the #Oppenheimer 31st #Annual #Healthcare #Conference https://t.co/G1Z9O3TOGj $CGEN @CompugenLtd March 8th 2021, 12:03pm |
|
@stock_titan $CGEN Compugen to Present at the Oppenheimer 31st Annual Healthcare Conference https://t.co/XH3tHbOXAl March 8th 2021, 12:03pm |
 |
@TitoElBandito @MarkGutman9 @Keubiko Great write up I'm smarter for reading it Also, I learned there is no borrow on $cgen March 4th 2021, 10:03pm |
|
@SickEconomics They need the jumbo funding because they're moving from identifying targets to developing drugs themselves. $CGEN… https://t.co/FXgv0HRhpI March 4th 2021, 8:03pm |
 |
@rt7683 @BigCForever Here's some small caps ARK owns >10% in. Disaster waiting to happen ? $CLLS $CGEN https://t.co/7XCyGCoVZX March 4th 2021, 6:03pm |
|
@ChartMill The technical rating of $CGEN is bad and it also does not present a quality setup at the moment.… https://t.co/gm0IASCFOo March 4th 2021, 2:03am |
 |
@tim41086372 Order in $CGEN $8.90 seems like a bottom tap PPS to me March 3rd 2021, 6:03pm |
 |
@TradeFlags TD BUY $CGEN at 9.41, Supp 8.96 Resis 13.21 R47 HiLo 25% T1Y 22 strong_buy 1.4 fwdPE -13.1 DIV N/A #Compugen L… https://t.co/mwpnSoDtVo March 3rd 2021, 3:03am |
DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC
2004 - 2021. All rights reserved.
Get the DrugPatentWatch Daily Briefing
Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …
Want insights into the biggest revenue-changing events?
Billions of dollars in sales can evaporate overnight as drug patents expire and competitors enter the market.
By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
➤ Free Trial
